FDA Approves New Treatment for People Ages 12 and Older With Moderate-to-Severe Atopic Dermatitis

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from AbbVie to bring you the latest research news quickly. PRESS RELEASE U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis – Approval of two dose strengths (15 mg and 30 mg) supported by efficacy and safety data from one of the largest registrational Phase 3 programs in atopic dermatitis, with more than 2,500 patients…

Lesen Sie weiter auf: FDA Approves New Treatment for People Ages 12 and Older With Moderate-to-Severe Atopic Dermatitis
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• AAFA Marks Day of Remembrance for Lives Lost to Asthma and Allergies
• How to Avoid Allergy and Asthma Triggers During Outdoor Parties and Cookouts
• Understanding Eosinophilic Asthma
• Tips on How to Use Your Inhaler to Get More Medicine Into Your Lungs for Better Asthma Control
• Advocacy Action Day for People With Asthma and Allergies
• Healthier Home Checklist: How to Improve Your Home’s Asthma and Allergy Hot Spots
• Ask the Expert Chat: How to Use Your Asthma and Allergy Medicines
• Top Questions About Using Asthma and Allergy Medicines
• Air Quality Awareness Sheds Light on How Environmental Injustice Affects People With Asthma
• The HEAL Program: AAFA’s Commitment to Health Equity for People With Asthma